September 18, 2020

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• A propensity score matched cohort study (n=303) found that, compared to patients receiving standard of care, patients receiving colchicine, an anti-inflammatory drug commonly used to prevent or treat gout, had a higher odds of being discharged at 28 days (OR=5.0, 95%CI: 1.25-20.1) and had lower odds of dying at 28 days (OR=0.2, 95% CI: 0.05-0.80).

Brunetti et al. (Sept 14, 2020). Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9092961